Lumateperone 42 mg in an Open-Label Switch Study in Patients with Stable Schizophrenia: Results by P...
Lumateperone 42 mg in an Open-Label Switch Study in Patients with Stable Schizophrenia: Results by Previous Antipsychotic
About this item
Full title
Author / Creator
Publisher
New York, USA: Cambridge University Press
Journal title
Language
English
Formats
Publication information
Publisher
New York, USA: Cambridge University Press
Subjects
More information
Scope and Contents
Contents
IntroductionLumateperone (LUMA) is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. An open-label study (Study 303) evaluated the safety and tolerability of LUMA in outpatients with stable schizophrenia who switched from previous antipsychotic (AP) treatment. This post ho...
Alternative Titles
Full title
Lumateperone 42 mg in an Open-Label Switch Study in Patients with Stable Schizophrenia: Results by Previous Antipsychotic
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2800552131
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2800552131
Other Identifiers
ISSN
1092-8529
E-ISSN
2165-6509
DOI
10.1017/S1092852923001645
